Merck is in advanced negotiations to acquire Seagen for $40 billion – WSJ
The Wall Street Journal reported on Wednesday that pharmaceutical major Merck & Co is in advanced discussions to acquire cancer-focused biotech startup Seagen Inc in a transaction that could be worth $40 billion or more.
Written by: Skylar Williams
Published on:
